This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakchbandi, I. A. Articles by Insogna, K. L. Search for Related Content PubMed PubMed Citation Articles by Nakchbandi, I. A. Articles by Insogna, K. L. Related Collections Calcium and Bone Metabolism

The Role of the Receptor Activator of Nuclear Factor-B Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism

Section of Endocrinology (I.A.N., K.L.I.), Department of Medicine, and Department of Surgery (B.K.), Yale University School of Medicine, New Haven, Connecticut 06520; Max-Planck Institute for Biochemistry (I.A.N.) and University of Heidelberg (I.A.N.), 69120 Heidelberg, Germany; and Osteoporosis Center (R.L.), Hamden, Connecticut 06518

Address all correspondence and requests for reprints to: Inaam Nakchbandi, M.D., F.A.C.P., Max-Planck Institute for Biochemistry and University of Heidelberg, Im Neuenheimer Feld 305, 2. OG, R 210, 69120 Heidelberg, Germany. E-mail: inaam.nakchbandi{at}urz.uni-heidelberg.de.

Context: The mechanisms of action of PTH on bone in vivo remain incompletely understood. The objective of this investigation was to examine changes in serum levels of receptor activator of nuclear factor-B ligand and osteoprotegerin (OPG) in primary hyperparathyroidism and their relationship to bone loss.

Patients and Methods: Twenty-nine patients with primary hyperparathyroidism had baseline circulating soluble receptor activator of nuclear factor-B ligand (sRANKL) and OPG measured. The relationship to biochemical markers of bone turnover and changes in bone mineral density over 2 yr was examined.

Results: Baseline sRANKL levels were elevated (1.7 ± 0.1 pmol/liter), whereas OPG remained in the normal range (5.6 ± 0.4 pmol/liter). Circulating sRANKL did not correlate with PTH but did correlate with markers of bone resorption (urine deoxypyridinoline cross-links: r = 0.51, P < 0.01; serum N-telopeptide of type I collagen: r = 0.37, P < 0.05). Furthermore, sRANKL correlated with both IL-6 and IL-6 soluble receptor (IL-6sR) (r = 0.47, P < 0.05 and r = 0.55, P < 0.005, respectively). Serum sRANKL levels also correlated with bone loss at the total femur (r = –0.53, P < 0.01). Lastly, a high value of sRANKL in combination with values of IL-6 and IL-6sR in the upper quartile (sRANKL 1.81 pg/ml, IL –6 11.8 pg/ml, and IL-6sR 45.6 ng/ml) defined a group of four women with significantly greater rates of bone loss at the total femur than the remaining patients (–2.7 ± 1.7% vs. +0.5 ± 0.3%; n = 4 vs. n = 19, P < 0.05).

Conclusion: Determination of circulating levels of sRANKL may be useful in identifying patients with mild primary hyperparathyroidism at greater risk for bone loss. The fact that circulating sRANKL did not correlate with PTH but did correlate with markers of bone resorption suggests that skeletal responsiveness to PTH may differ in this disease.

This article has been cited by other articles:

				G. El-Hajj Fuleihan Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms? J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3302 - 3304. [Full Text] [PDF]